Construction of tissue‐engineered lymphatic vessel using human adipose derived stem cells differentiated lymphatic endothelial like cells and decellularized arterial scaffold: A preliminary study

Abstract

We have previously demonstrated that human adipose-derived stem cells (hADSCs) can be differentiated into lymphatic endothelial like cells. The purpose of this study was to investigate the feasibility of utilizing the induced lymphatic endothelial like cells and decellularized arterial scaffold to construct the tissue-engineered lymphatic vessel. The hADSCs were isolated from adipose tissue in healthy adults and were characterized the multilineage differentiation potential. Decellularized arterial scaffold was prepared using the Triton x-100 method. ADSCs were differentiated into lymphatic-like endothelial cells, and the induced cells were then seeded onto the decellularized arterial scaffold to engineer the lymphatic vessel. The histological analyses were performed to examine the endothelialized construct. The decellularized arterial scaffold was successfully obtained and was able to maintain its vessel morphology. The isolated ADSCs can be differentiated into osteocytes and adipocytes. After seeding onto the scaffold, the seeded cells attached and grew well on the decellularized arterial scaffold. Our preliminary results demonstrated that the induced lymphatic endothelial like cells combined with decellularized arterial scaffold could be utilized to successfully engineer the lymphatic vessel. Our findings may be helpful for the development of tissue-engineering of the lymphatic graft.

Delivery of vascular endothelial growth factor (VEGFC) via engineered exosomes improves lymphedema

“…node transfer are considered the critical approaches for lymphedema (5). However, lymphatic venous anastomosis often results in lymphatic occlusion, and rebuilding of the communication between the new lymph node and the original lymphatic system remains a significant challenge (6)(7)(8)(9). Therefore, novel strategies still must improve the therapy of lymphedema.…”

Lymphatic Tissue Engineering: A Further Step for Successful Lymphedema Treatment

“…Adipose-derived stem cells (ADSC) obtained from liposuction have successfully been differentiated into LEC under in vitro stimulation with recombinant VEGF-C and basic fibroblast growth factor (bFGF). 40 An anti-LYVE1-positive phenotype was confirmed by immunofluorescence staining.…”

“…This stands in contrast to nonbiodegradable vessel grafts, which have the advantage of maintaining its mechanical properties, yet high rates of infection and longtime patency, especially in vessels with small diameters, remain an issue. 67 As an alternative to de novo construction of a scaffold, arteries of small diameter have been decellularized with Triton X for use as a scaffold by Yang et al 40 With all cells removed, the morphology of collagen and elastic fibers remained intact and seeded LEC derived from human ADSCs formed an endothelial lining. The authors conclude that the next step might be to use decellularized venous scaffolds as done similarly for tissue engineering blood vessels 68 to achieve a closer resemblance to lymphatic vessels, including valves.…”

Adipose-derived stem cell therapy shows promising results for secondary lymphedema

“…Secondary lymphedema remains a serious global disease with primary lymphedema due to genetic defects accounting for only a subset of those afflicted[ 1 , 2 ]. The common causes of secondary lymphedema are attributed to cancer therapy, parasite infection, and trauma[ 3 ]. Most sufferers are those with cancer who require radiotherapy or lymph node dissection[ 4 ].…”